Literature DB >> 8084406

Oligodendroglioma: the Rotterdam-Dijkzigt experience.

J M Kros1, H Pieterman, C G van Eden, C J Avezaat.   

Abstract

In a retrospective study of 82 cases of oligodendroglioma, the influences of tumor size, site, and grade, the age of the patient, the extent of surgical excision, and the effect of additional radiation therapy on the clinical course, as well as their dependencies, were investigated. Tumor grade and tumor site significantly affected the survival rates of the patients. When tumor site was kept constant by distinguishing between frontal and nonfrontal localized oligodendrogliomas, the grading system still showed discriminating power. Conversely, when controlled for grade, the frontal site appeared to be favorable for prognosis. Age was only faintly correlated with survival, with younger patients tending to survive longer. This was compatible with the finding that, in young patients, more frontal localized tumors were found and that older patients had oligodendrogliomas with higher grades. Tumor volumes did not correlate with survival. No correlation between tumor volume and tumor grade was found. Patients who had undergone a decompression tended toward longer survival, although this trend did not reach significance. No beneficial effect of radiation therapy on the survival rate was demonstrable.

Entities:  

Mesh:

Year:  1994        PMID: 8084406     DOI: 10.1227/00006123-199406000-00002

Source DB:  PubMed          Journal:  Neurosurgery        ISSN: 0148-396X            Impact factor:   4.654


  18 in total

1.  The prognostic significance of vascular endothelial growth factor (VEGF C-1) immunoexpression in oligodendroglioma. An analysis of 91 cases.

Authors:  A Korshunov; A Golanov
Journal:  J Neurooncol       Date:  2000-05       Impact factor: 4.130

Review 2.  Low grade gliomas: functional mapping resection strategies, extent of resection, and outcome.

Authors:  M S Berger; R C Rostomily
Journal:  J Neurooncol       Date:  1997-08       Impact factor: 4.130

3.  Impact of chromosome 1p status in response of oligodendroglioma to temozolomide: preliminary results.

Authors:  Ali Chahlavi; Andrew Kanner; David Peereboom; Susan M Staugaitis; Paul Elson; Gene Barnett
Journal:  J Neurooncol       Date:  2003-02       Impact factor: 4.130

4.  The prognostic role of vessel productive changes and vessel density in oligodendroglioma.

Authors:  D Schiffer; I Bosone; A Dutto; N Di Vito; A Chiò
Journal:  J Neurooncol       Date:  1999-09       Impact factor: 4.130

Review 5.  Biology, genetics and imaging of glial cell tumours.

Authors:  C Walker; A Baborie; D Crooks; S Wilkins; M D Jenkinson
Journal:  Br J Radiol       Date:  2011-12       Impact factor: 3.039

6.  Postoperative radiotherapy and chemotherapy in the management of oligodendroglioma: single institutional review of 88 patients.

Authors:  Gokhan Ozyigit; Cem Onal; Murat Gurkaynak; Figen Soylemezoglu; Faruk Zorlu
Journal:  J Neurooncol       Date:  2005-11       Impact factor: 4.130

7.  Oligodendrogliomas. Part II: A new grading system based on morphological and imaging criteria.

Authors:  C Daumas-Duport; M L Tucker; H Kolles; P Cervera; F Beuvon; P Varlet; N Udo; M Koziak; J P Chodkiewicz
Journal:  J Neurooncol       Date:  1997-08       Impact factor: 4.130

Review 8.  Pathology and molecular genetics of oligodendroglial tumors.

Authors:  Christian Hartmann; Wolf Mueller; Andreas von Deimling
Journal:  J Mol Med (Berl)       Date:  2004-10       Impact factor: 4.599

9.  Genetic signature of oligoastrocytomas correlates with tumor location and denotes distinct molecular subsets.

Authors:  Wolf Mueller; Christian Hartmann; Annegret Hoffmann; Wolfgang Lanksch; Jürgen Kiwit; Jörg Tonn; Julian Veelken; Johannes Schramm; Michael Weller; Otmar D Wiestler; David N Louis; Andreas von Deimling
Journal:  Am J Pathol       Date:  2002-07       Impact factor: 4.307

Review 10.  The impact of technical adjuncts in the surgical management of cerebral hemispheric low-grade gliomas of childhood.

Authors:  M S Berger
Journal:  J Neurooncol       Date:  1996 May-Jun       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.